FDA Requests Additional Information Regarding AFREZZA(TM) in Complete Response … – MarketWatch (press release)

March 15, 2010

FDA Requests Additional Information Regarding AFREZZA(TM) in Complete Response
MarketWatch (press release)
The letter did not require any additional pre-marketing clinical studies in order for the FDA to complete its review of the NDA. As recommended by the FDA,
FDA Seeks Additional Information On MannKind's Insulin Therapy Afrezza – UpdateRTT News
MannKind's Insulin Afrezza Fails to Win ApprovalBusinessWeek

all 62 news articles »

Leave a Comment

Security Code:

Previous post:

Next post: